Stephen D. Shafran

Stephen D. Shafran

Auto-generated profile, based on publicly available information

Stephen D. Shafran

Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2004 in Journal of Clinical Virology
Verified
Journal Article
Closed access
SSStephen D. Shafran
Stephen D. Shafran
STStephen K. Tyring
Stephen K. Tyring
RARichard Ashton
Richard Ashton
JDJacque Decroix
Jacque Decroix
CFChistine Forszpaniak
Chistine Forszpaniak
DCDaniel Candaele
Daniel Candaele

9 June 2015 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
SSStephen D. Shafran
Stephen D. Shafran
Phase 3 trials of direct acting antiviral drugs (DAAs) for hepatitis C virus (HCV) excluded patients coinfected with human immunodeficiency virus (HIV). After approval, small trials were done in HIV-HCV coinfected patients. The status quo results in delayed access to DAAs for HIV coinfected patients, a group with more rapid progression of liver disease. This article reviews all approved DAAs and compares sustained virological response (SVR) rates in the HIV coinfected with those in the HCV monoinfected treated with the same regimen for the same HCV genotype. SVR rates in HCV genotype 1 to 4 are virtually identical in the HIV co-infected as in the HCV monoinfected, regardless of whether the regimens contain interferon. Because HIV coinfection does not affect SVR rates or toxicity with DAA-containing therapy, excluding HIV coinfected patients from clinical trials of DAA-containing anti-HCV therapy is discriminatory and unnecessary. Rather, HIV coinfection is one of many comorbidities that occur in some patients with HCV infection.

4 July 2016 in Canadian Journal of Infectious Diseases and Medical Microbiology
Verified
Journal Article
Open access
PDF file
MHMark Hull
Mark Hull
SSStephen Shafran
Stephen Shafran
AWAlex Wong
Alex Wong
ATAlice Tseng
Alice Tseng
PGPierre Giguère
Pierre Giguère
CCCurtis Cooper
Curtis Cooper
Background. Hepatitis C virus (HCV) coinfection occurs in 20–30% of Canadians living with HIV and is responsible for a heavy burden of morbidity and mortality.Purpose. To update national standards for management of HCV-HIV coinfected adults in the Canadian context with evolving evidence for and accessibility of effective and tolerable DAA therapies. The document addresses patient workup and treatment preparation, antiviral recommendations overall and in specific populations, and drug-drug interactions.Methods. A standing working group with HIV-HCV expertise was convened by The Canadian Institute of Health Research HIV Trials Network to review recently published HCV antiviral data and update Canadian HIV-HCV Coinfection Guidelines.Results. The gap in sustained virologic response between HCV monoinfection and HIV-HCV coinfection has been eliminated with newer HCV antiviral regimens. All coinfected individuals should be assessed for interferon-free, Direct Acting Antiviral HCV therapy. Regimens vary in content, duration, and success based largely on genotype. Reimbursement restrictions forcing the use of pegylated interferon is not acceptable if optimal patient care is to be provided.Discussion. Recommendations may not supersede individual clinical judgement. Treatment advances published since December 2015 are not considered in this document.

15 April 2007 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
SSStephen D Shafran
Stephen D Shafran
Approximately 25% to 35% of HIV-infected persons in developed countries are coinfected with hepatitis C virus (HCV). HCV liver disease is accelerated by HIV coinfection, especially at low CD4 cell counts. Highly active antiretroviral therapy (HAART) dramatically reduces HIV-related mortality, and liver disease has emerged as a major cause of death in HIV/HCV-coinfected persons. Anti-HCV therapy with pegylated interferon plus ribavirin can cure HCV infection in up to 40% of coinfected patients; however, only approximately 10% of coinfected patients are considered candidates. Hence, HCV therapy cures approximately 4% of coinfected patients. Eleven cohort studies have shown that HAART is associated with a reduced rate of progression of HCV liver disease, and 4 of these studies have demonstrated a reduction in liver-related mortality. Although offering HCV therapy to the few eligible HIV/HCV-coinfected patients is important, early initiation of HAART in coinfected patients has a greater public health impact in reducing liver-related mortality than in curing HCV infection in approximately 4% of these patients.

16 August 2022 in HIV Medicine
Verified
Journal Article
Closed access
SSStephen D. Shafran
Stephen D. Shafran
CHChristine A. Hughes
Christine A. Hughes

14 September 2017 in Journal of Viral Hepatitis
Verified
Journal Article
Closed access
PDF file
SSS. D. Shafran
S. D. Shafran
DSD. Shaw
D. Shaw
MCM. Charafeddine
M. Charafeddine
KAK. Agarwal
K. Agarwal
GFG. R. Foster
G. R. Foster
EGE. Gane
E. Gane